An Open-label, Randomized, Single-dose, 4-way Crossover Study to Assess the Relative Bioavailability of Axelopran and Oxycodone Administered as a Fixed-Dose Combination and as Individual Components to Healthy Subjects with a Naltrexone Block Under Fasting Conditions
100 Clinical Results associated with Theravance Biopharma R&D, Inc.
0 Patents (Medical) associated with Theravance Biopharma R&D, Inc.
100 Deals associated with Theravance Biopharma R&D, Inc.
100 Translational Medicine associated with Theravance Biopharma R&D, Inc.